Serina Therapeutics’ Chief Scientific Officer Disposes of Shares Amid NYSE Compliance Concerns
Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, completed the sale of a portion of his shares and exercised stock options on January 20 and 21, 2026. This insider activity coincides with the company receiving a notice from the NYSE citing deficiencies related to stockholders' equity and recent financial performance. Additionally…